Structure-based drug discovery of ApoE4 inhibitors from the plant compounds

Medicinal Chemistry Research

Volumn 21, Issue 6, 2012, Pages 825-833

  Singh, Kh Dhanachandra ^a   Karthikeyan, M ^a   Kirubakaran, P ^a   Sathya, V ^b   Nagamani, S ^b  

^a ALAGAPPA UNIVERSITY   (India)

^b Dr GR Damodaran College of Science   (India)

Author keywords

ADME; Alzheimer's diseases; ApoE4; Curcumin; Induce fit docking

Indexed keywords

ACEPHATE; AMBENONIUM; ANABASINE; APOLIPOPROTEIN E4; APOLIPOPROTEIN E4 INHIBITOR; ATROPINE; CANNABICHROMENE; CANNABICYCLOL; CANNABIDIOL; CANNABIGEROL; CANNABINOL; CHOLINESTERASE INHIBITOR; CODEINE; CURCUMIN; DONEPEZIL; GALANTAMINE; GERMACRENE D; HYOSCYAMINE; IBOGAINE; MORPHINE; NATURAL PRODUCT; NICOTINE; PHENSERINE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; TETRAHYDROCANNABINOL; TETRAHYDROCANNABIVARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOACANGINE;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; DRUG ABSORPTION; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; HYDROGEN BOND; INDUCED FIT DOCKING; MOLECULAR DOCKING; NONHUMAN; PHYSICAL CHEMISTRY; PLANT PRODUCT;

EID: 84861874829     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9595-3     Document Type: Article

References (36)

1. Ahmed ARH, MacGowan SH, Culpan D, Jones RW, Wilcock GK (1999) The-491A/T polymorphism of the Apolipoprotein E gene is associated with the ApoEepsilon4 allele and Alzheimer's disease. Neurosci Lett 263:217-219 (Pubitemid 29158968)
2. Bales KR (2010) Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease. Neuropharmacology 59:295-302
3. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH (2010) The Alzheimer's disease neuroimaging initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement 6:257-264
4. Birks J, Harvey RJ (2006) Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev Issue 1. Art. No.: CD001190. doi:10.1002/14651858.CD001190.pub2 (Pubitemid 46841367)
5. Birks J, Evans JG, Iakovidou V, Tsolaki M (2009) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. Issue 2. Art. No.: CD001191. doi:10.1002/14651858.CD001191.pub2
6. da Silva CHTDP, da Silva VB, Resende J, Rodrigues PF, Bononi FC, Benevenuto CG, Taft CA (2010) Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy. J Mol Graph Model 28:513-523
7. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno JG, Asher SW, Beaver C, Hamilton D, Bergman SM, Roger LF, Black SE, Carr S, Winchester T, Layne E, Clark C, Dexter J, DuBoff EA, Hendrie H, Caress J, Shatz R, Hanna GR, Brashear HR, Damgaard P, Donnelly K, Burch K, Homan RW, McSweeney AJ, Ann Barczak M, Mattes JA, Hermann AM, Mohr E, Mendis T, Roberts J, Begin L, Sampson M, Ott BR, Lannon MC, Prendergast JJ, Madan S, Hanning R, Martinez W, Stone R, Winner P, Zuniga J, Mate LJ, Ehlert BJ, Lessard C, Seltze B, Taylor JR, Calabrese VP, Harkins SW, Weis SJ, Slade W, Sommer BR, Wichter M, Schwartz M, Eastman J, Thein SG Jr, Williams G, Dewar JA, Foster NL, Bluemlein LA, Gelb DJ, Berent S, Giordani B, Baron BA, Myers S (1992) A controlled trial of tacrine in Alzheimer's Disease. JAMA 268:2523-2529
8. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. J Med Chem 47:1739-1749 (Pubitemid 38380917)
9. Halgren TA, Murphy RB, Friesne RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750-1759 (Pubitemid 38380918)
10. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y (2003) Carboxyl-terminaltruncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 100:10966-10971 (Pubitemid 37140136)
11. Hayes JM, Stein M, Weiser JR (2004) Accurate calculations of ligand binding free energies: chiral separation with enantioselective receptors. J Phys Chem A 108:3572-3580
12. Huang S, Li J, Sun L, Ye J, Fleisher A, Wu T, Chen K, Reiman E (2010) Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation. Neuroimage 50:935-949
13. Khorana N, Markmee S, Ingkaninan K, Ruchirawat S, Kitbunnadaj R, Pullagurla MR (2009) Evaluation of a new lead for acetylcholinesterase inhibition. Med Chem Res 18(3):231-241
14. Kie H, van Robert R, Nicolaas PLGV (2009) Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement 5:348-360
15. Lagunin A, Stepanchikova A, Filimonov D, Poroikov V (2000) PASS: prediction of activity spectra for biologically active substances. Bioinformatics 16:747-748
16. Lauria A, Ippolito M, Almerico AM (2009) Inside the Hsp90 inhibitors binding mode through induced fit docking. J Mol Graph Model 27:712-722
17. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25 (Pubitemid 27046991)
18. Lukiw WJ, Pappolla M, Pelaez RP, Bazan NG (2005) Alzheimer's disease-a dysfunction in cholesterol and lipid metabolism. Cell Mol Neurobiol 25:475-483 (Pubitemid 41186260)
19. Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, Tang S, Le K, Chen S, Pi R, Liu P (2009) Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alphasecretase in vivo and in vitro. Neurosci Lett 452:90-95
20. Mishra S, Palanivelu K (2008) The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol 11: 13-19 (Pubitemid 351550812)
21. Poirier J (2005) Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 26:355-361 (Pubitemid 40082719)
22. Poroikov VV, Filimonov DA, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, Borodina YV, Stepanchikova AV, Nicklaus MC (2002) PASS biological activity spectrum predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci 43:228-236
23. QikProp (2009) version 3.1, Schrödinger, LLC, New York
24. Refolo L, Fillit H (2004) Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease. J Mol Neurosci 23: 151-155 (Pubitemid 41389381)
25. Reiman EM, Chen K, Caselli RJ, Alexander GE, Bandy D, Adamson JL, Lee W, Cannon A, Stephan EA, Stephan DA, Papassotiropoulos A (2008) Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage 40:1214-1221
26. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653 (Pubitemid 23315843)
27. Sengupta D, Verma D, Naik PK (2007) Docking mode of delvardine and its analogues into the p66 domain of HIV-1 reverse transcriptase: screening using molecular mechanics-generalized born/surface area and absorption, distribution, metabolism and excretion properties. J Biosci 32(7):1307-1316
28. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102 (Pubitemid 23260862)
29. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD (1994) Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 91:11183-11186
30. Tsuyoshi H, Kenjiro O, Masahito Y (2010) Curcumin and Alzheimer's disease. CNS Neurosci Ther 16:285-297. doi:10.1111/j.1755-5949.2010.00147.x
31. Veera Venkata Ratnam B, Juan T, David W, Olga P, Jessica W, Kathy C, Norman JH (2009) ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging 30:591-599
32. Wang H, Aslanian R, Madison VS (2008) Induced-fit docking of mometasone furoate and further evidence for glucocorticoid receptor 17alpha pocket flexibility. J Mol Graph Model 27: 512-521
33. Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M (2010) The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6:202-211
34. Weisgraber KH, Mahley RW (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 10:1485-1494 (Pubitemid 26384445)
35. Xu PT, Li Y, Qin XJ, Scherzer CR, Xu H, Schmechel DE, Hulette CM, Ervin J, Gullans SR, Haines J, Pericak-Vance MA, Gilbert JR (2006) Differences in apolipoprotein E3/3 and E4/4 allelespecific gene expression in hippocampus in Alzheimer disease. Neurobiol Dis 21:256-275 (Pubitemid 43099851)
36. Zarotsky V, Sramek JJ, Cutler NR (2003) Galantamine hydrobromide: an agent for Alzheimer's disease. Am J Health Syst Pharm 60:446-452 (Pubitemid 36752907)